nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2010 | Focus on

PET-guided prostate cancer radiotherapy: technological innovations for dose delivery optimisation

verfasst von: Giovanni Lucignani, Habib Zaidi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Excerpt

I hope that our contributions, among other developments, will be used by many to reduce suffering, improve our health and extend the productivity and fulfilment of our lives. Equally important, I hope that the new biological insights will yield a better understanding of ourselves as human beings and of our relationship to our environment, so that we may become better stewards of a fragile Earth [1].

Mario R. Capecchi

…

http://nobelprize.org/nobel_prizes/medicine/laureates/2007/capecchi-lecture.html.

Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging. 2009;53(2):245–68.PubMed

Park H, Meyer CR, Wood D, Khan A, Shah R, Hussain H, et al., Validation of automatic target volume definition as demonstrated for (11)C-choline PET/CT of human prostate cancer using multi-modality fusion techniques. Acad Radiol. 2010 Feb 24. [Epub ahead of print] doi:10.1016/j.acra.2010.01.003.

Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50(10):1585–93.CrossRefPubMed

Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93(2):220–5.CrossRefPubMed

Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol. 2009;4:34.CrossRefPubMed

Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer—evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93(2):213–9.CrossRefPubMed

Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93(2):234–40.CrossRefPubMed

Jani AB, Fox TH, Whitaker D, Schuster DM. Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design. Clin Nucl Med. 2009;34(5):279–84.CrossRefPubMed

10.

Hsi WC, Indelicato DJ, Vargas C, Duvvuri S, Li Z, Palta J. In vivo verification of proton beam path by using post-treatment PET/CT imaging. Med Phys. 2009;36(9):4136–46.CrossRefPubMed

11.

Zaidi H, Vees H, Wissmeyer M. Molecular PET/CT imaging-guided radiation therapy treatment planning. Acad Radiol. 2009;16(9):1108–33.CrossRefPubMed

12.

Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37.

Titel: PET-guided prostate cancer radiotherapy: technological innovations for dose delivery optimisation
verfasst von: Giovanni Lucignani
Habib Zaidi
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1478-1

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1

68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours

‘Running on empty’

18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence

Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma

Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma